Q1 EPS Forecast for MAIA Biotechnology Lifted by Analyst

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Research analysts at Diamond Equity increased their Q1 2025 earnings per share estimates for shares of MAIA Biotechnology in a research report issued to clients and investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond now expects that the company will post earnings of ($0.18) per share for the quarter, up from their previous forecast of ($0.25). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($0.75) EPS.

MAIA Biotechnology Price Performance

Shares of MAIA Biotechnology stock opened at $1.63 on Thursday. The company has a market capitalization of $42.64 million, a PE ratio of -1.18 and a beta of 0.20. The business’s 50-day moving average price is $1.85. MAIA Biotechnology has a 1-year low of $1.46 and a 1-year high of $5.99.

Institutional Investors Weigh In On MAIA Biotechnology

A number of hedge funds have recently added to or reduced their stakes in MAIA. XTX Topco Ltd bought a new position in MAIA Biotechnology in the 3rd quarter valued at $31,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology during the fourth quarter worth $77,000. Finally, Geode Capital Management LLC lifted its stake in shares of MAIA Biotechnology by 22.9% during the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after acquiring an additional 35,821 shares during the period. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.